110 related articles for article (PubMed ID: 7129644)
1. Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses.
Hofstra W; de Vries-Hospers HG; van der Waaij D
Infection; 1982; 10(4):223-7. PubMed ID: 7129644
[TBL] [Abstract][Full Text] [Related]
2. Salivary concentrations of amphotericin B following its use as an oral lozenge.
de Vries-Hospers HG; van der Waaij D
Infection; 1980; 8(2):63-5. PubMed ID: 6993365
[TBL] [Abstract][Full Text] [Related]
3. [Amphotericin B level in feces and serum during oral administration in newborns at risk].
Blaschke-Hellmessen R; Schwarze R
Mycoses; 1994; 37 Suppl 1():84-8. PubMed ID: 7854372
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of nystatin in faeces after oral administration of various doses of nystatin.
Hofstra W; de Vries-Hospers HG; van der Waaij D
Infection; 1979; 7(4):166-70. PubMed ID: 511333
[TBL] [Abstract][Full Text] [Related]
5. The effect of amphotericin B on the fungal flora in feces.
Bodey GP
Clin Pharmacol Ther; 1969; 10(5):675-80. PubMed ID: 5817629
[No Abstract] [Full Text] [Related]
6. Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer.
Phillips A; Fiorello CV; Baden RM; Liu JH; Burmas NC; Ruvalcaba CA; Monroy R; Mohr FC; Gehring R; Delplanque JP; Clemons KV; Stevens DA; Tell LA
Med Mycol; 2018 Apr; 56(3):322-331. PubMed ID: 28992055
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic and therapeutic effects of oral administration of amphotericin B in mycosis associated with hematologic diseases. Study Group of Mycosis in Hematologic Disease.
Urabe A; Takaku F; Mizoguchi H; Nomura T; Ogawa T; Maekawa T; Omine M; Miura Y; Hirashima K; Takatani O
Jpn J Antibiot; 1990 Jan; 43(1):116-30. PubMed ID: 2190013
[TBL] [Abstract][Full Text] [Related]
8. Effects of amphotericin B gargles on oral colonization of Candida albicans in asthmatic patients on steroid inhalation therapy.
Fukushima C; Shimoda T; Kawano T; Tomari S; Mitsuta K; Obase Y; Matsuo N; Matsuse H; Kohno S
Respiration; 2001; 68(5):465-70. PubMed ID: 11694807
[TBL] [Abstract][Full Text] [Related]
9. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.
Epstein JB; Truelove EL; Hanson-Huggins K; Mancl LA; Chen A; Press OW; Petersdorf SH; Fritsche TR; Epstein JD
Support Care Cancer; 2004 Jul; 12(7):517-25. PubMed ID: 15108100
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.
Baley JE; Meyers C; Kliegman RM; Jacobs MR; Blumer JL
J Pediatr; 1990 May; 116(5):791-7. PubMed ID: 2329429
[TBL] [Abstract][Full Text] [Related]
11. Absorption of orally administered amphotericin B lozenges.
Ching MS; Raymond K; Bury RW; Mashford ML; Morgan DJ
Br J Clin Pharmacol; 1983 Jul; 16(1):106-8. PubMed ID: 6882617
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group.
Philpott-Howard JN; Wade JJ; Mufti GJ; Brammer KW; Ehninger G
J Antimicrob Chemother; 1993 Jun; 31(6):973-84. PubMed ID: 8360134
[TBL] [Abstract][Full Text] [Related]
13. [Candida in feces following oral administration of premixed tetracycline and amphotericin B preparation].
Fukaya K; Kitamoto O
Kansenshogaku Zasshi; 1970 Jan; 43(10):283-8. PubMed ID: 4985501
[No Abstract] [Full Text] [Related]
14. [Supplemental studies on amphotericin B].
Fukaya K
Jpn J Antibiot; 1972 Feb; 25(1):17-20. PubMed ID: 4537361
[No Abstract] [Full Text] [Related]
15. [Differentiation of intestinal candidial colonization from invasive candidiasis by measuring serum level of D-arabinitol in combination with oral administration of low dose amphotericin B].
Fujita N; Hamada K; Takahashi H; Yoshimura M; Nakanishi S; Gotoh H; Oku N; Inaba T; Muragashira S; Ito K
Rinsho Byori; 1991 Aug; 39(8):895-7. PubMed ID: 1920890
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase.
de Vries-Hospers HG; van der Waaij D
Infection; 1978; 6(1):16-20. PubMed ID: 631898
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
18. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B.
Chang T; Olson JA; Proffitt RT; Adler-Moore JP
Med Mycol; 2010 Mar; 48(2):430-5. PubMed ID: 20141377
[TBL] [Abstract][Full Text] [Related]
19. A multi-centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole.
Flynn E; Marciniak A; Barbabietola G; Oppenheim BA; Roberts C; Barker K
J Clin Nurs; 2009 Apr; 18(8):1168-79. PubMed ID: 19017372
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of oral amphotericin B with serial measurement of the serum concentration in patients with leukemia and related disorders].
Okuda T; Nishigaki H; Yokota S; Horiike S; Yashige H; Nishida K; Maekawa T; Tsuda S; Taniwaki M; Sonoda Y
Jpn J Antibiot; 1987 Sep; 40(9):1644-50. PubMed ID: 3694788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
